Որոնման արդյունքները - Lockerman, Elizabeth L
- Ցուցադրվում են 1 - 12 արդյունքները 12
-
1
Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive cancer Katayama, Ryohei, Kobayashi, Yuka, Friboulet, Luc, Lockerman, Elizabeth. L., Koike, Sumie, Shaw, Alice T., Engelman, Jeffrey A., Fujita, Naoya
Հրապարակվել է 2014Տեքստ -
2
The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies Niederst, Matthew J., Hu, Haichuan, Mulvey, Hillary E., Lockerman, Elizabeth L., Garcia, Angel R., Piotrowska, Zofia, Sequist, Lecia V., Engelman, Jeffrey A.
Հրապարակվել է 2015Տեքստ -
3
Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways Rothenberg, S Michael, Concannon, Kyle, Cullen, Sarah, Boulay, Gaylor, Turke, Alexa B, Faber, Anthony C, Lockerman, Elizabeth L, Rivera, Miguel N, Engelman, Jeffrey A, Maheswaran, Shyamala, Haber, Daniel A
Հրապարակվել է 2015Տեքստ -
4
Two novel ALK mutations mediate acquired resistance to the next generation ALK inhibitor alectinib Katayama, Ryohei, Friboulet, Luc, Koike, Sumie, Lockerman, Elizabeth L., Khan, Tahsin M., Gainor, Justin F., Iafrate, A. John, Takeuchi, Kengo, Taiji, Makoto, Okuno, Yasushi, Fujita, Naoya, Engelman, Jeffrey A., Shaw, Alice T.
Հրապարակվել է 2014Տեքստ -
5
CDK 4/6 inhibitors sensitize PIK3CA Mutant Breast Cancer to PI3K inhibitors Vora, Sadhna R., Juric, Dejan, Kim, Nayoon, Mino-Kenudson, Mari, Huynh, Tiffany, Costa, Carlotta, Lockerman, Elizabeth L., Pollack, Sarah F., Liu, Manway, Li, Xiaoyan, Lehar, Joseph, Wiesmann, Marion, Wartmann, Markus, Chen, Yan, Cao, Z. Alexander, Pinzon-Ortiz, Maria, Kim, Sunkyu, Schlegel, Robert, Huang, Alan, Engelman, Jeffrey A.
Հրապարակվել է 2014Տեքստ -
6
Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1 Awad, Mark M., Katayama, Ryohei, McTigue, Michele, Liu, Wei, Deng, Ya-Li, Brooun, Alexei, Friboulet, Luc, Huang, Donghui, Falk, Matthew D., Timofeevski, Sergei, Wilner, Keith D., Lockerman, Elizabeth L., Khan, Tahsin M., Mahmood, Sidra, Gainor, Justin F., Digumarthy, Subba R., Stone, James R., Mino-Kenudson, Mari, Christensen, James G., Iafrate, A. John, Engelman, Jeffrey A., Shaw, Alice T.
Հրապարակվել է 2013Տեքստ -
7
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer Friboulet, Luc, Li, Nanxin, Katayama, Ryohei, Lee, Christian C., Gainor, Justin F., Crystal, Adam S., Michellys, Pierre-Yves, Awad, Mark M., Yanagitani, Noriko, Kim, Sungjoon, Pferdekamper, AnneMarie C., Li, Jie, Kasibhatla, Shailaja, Sun, Frank, Sun, Xiuying, Hua, Su, McNamara, Peter, Mahmood, Sidra, Lockerman, Elizabeth L., Fujita, Naoya, Nishio, Makoto, Harris, Jennifer L., Shaw, Alice T., Engelman, Jeffrey A.
Հրապարակվել է 2014Տեքստ -
8
Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third Generation EGFR Inhibitor Piotrowska, Zofia, Niederst, Matthew J., Karlovich, Chris A., Wakelee, Heather A., Neal, Joel W., Mino-Kenudson, Mari, Fulton, Linnea, Hata, Aaron N., Lockerman, Elizabeth L., Kalsy, Anuj, Digumarthy, Subba, Muzikansky, Alona, Raponi, Mitch, Garcia, Angel R., Mulvey, Hillary E., Parks, Melissa K., DiCecca, Richard H., Dias-Santagata, Dora, Iafrate, A. John, Shaw, Alice T., Allen, Andrew R., Engelman, Jeffrey A., Sequist, Lecia V.
Հրապարակվել է 2015Տեքստ -
9
Patient-derived Models of Acquired Resistance Can Identify Effective Drug Combinations for Cancer Crystal, Adam S., Shaw, Alice T., Sequist, Lecia V., Friboulet, Luc, Niederst, Matthew J., Lockerman, Elizabeth L., Frias, Rosa L., Gainor, Justin F., Amzallag, Arnaud, Greninger, Patricia, Lee, Dana, Kalsy, Anuj, Gomez-Caraballo, Maria, Elamine, Leila, Howe, Emily, Hur, Wooyoung, Lifshits, Eugene, Robinson, Hayley E., Katayama, Ryohei, Faber, Anthony C., Awad, Mark M., Ramaswamy, Sridhar, Mino-Kenudson, Mari, Iafrate, A. John, Benes, Cyril H., Engelman, Jeffrey A.
Հրապարակվել է 2014Տեքստ -
10
Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations Ahronian, Leanne G., Sennott, Erin M., Van Allen, Eliezer M., Wagle, Nikhil, Kwak, Eunice L., Faris, Jason E., Godfrey, Jason T., Nishimura, Koki, Lynch, Kerry D., Mermel, Craig H., Lockerman, Elizabeth L., Kalsy, Anuj, Gurski, Joseph M., Bahl, Samira, Anderka, Kristin, Green, Lisa M., Lennon, Niall J., Huynh, Tiffany G., Mino-Kenudson, Mari, Getz, Gad, Dias-Santagata, Dora, Iafrate, A. John, Engelman, Jeffrey A., Garraway, Levi A., Corcoran, Ryan B.
Հրապարակվել է 2015Տեքստ -
11
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer Niederst, Matthew J., Sequist, Lecia V., Poirier, John T., Mermel, Craig H., Lockerman, Elizabeth L., Garcia, Angel R., Katayama, Ryohei, Costa, Carlotta, Ross, Kenneth N., Moran, Teresa, Howe, Emily, Fulton, Linnea E., Mulvey, Hillary E., Bernardo, Lindsay A., Mohamoud, Farhiya, Miyoshi, Norikatsu, VanderLaan, Paul A., Costa, Daniel B., Jänne, Pasi A., Borger, Darrell R., Ramaswamy, Sridhar, Shioda, Toshi, Iafrate, Anthony J., Getz, Gad, Rudin, Charles M., Mino-Kenudson, Mari, Engelman, Jeffrey A.
Հրապարակվել է 2015Տեքստ -
12
Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM Song, Kyung-A, Niederst, Matthew J., Lochmann, Timothy L., Hata, Aaron N., Kitai, Hidenori, Ham, Jungoh, Floros, Konstantinos V., Hicks, Mark A., Hu, Haichuan, Mulvey, Hillary E., Drier, Yotam, Heisey, Daniel A.R., Hughes, Mark T., Patel, Neha U., Lockerman, Elizabeth L., Garcia, Angel, Gillepsie, Shawn, Archibald, Hannah L., Gomez-Caraballo, Maria, Nulton, Tara J., Windle, Brad E., Piotrowska, Zofia, Sahingur, Sinem E., Taylor, Shirley M., Dozmorov, Mikhail, Sequist, Lecia V., Bernstein, Bradley, Ebi, Hiromichi, Engelman, Jeffrey A., Faber, Anthony C.
Հրապարակվել է 2017Տեքստ